Applied Therapeutics has previously said it hoped to be able to file for accelerated FDA approval based on biomarker data showing that AT-007 was able to reduce levels of galactitol, the main ...

Applied Therapeutics has been sent a warning letter from the FDA over a clinical trial of its rare disease therapy govorestat, which was rejected by the agency last week. The letter – addressed ...

Applied Therapeutics (APLT) (ISIN: US03828A1016)股票专题，提供今日Applied Therapeutics(APLT) (ISIN: US03828A1016)股票最新股价查询，实时市场行情，走势图表，及Applied Therapeutics Inc(APLT) (ISIN: ...

With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia treatment are ...

At close: February 25 at 4:00:02 PM EST ...

XORTX Therapeutics (XRTX) has submitted a Type C ... has advanced to the point where a Type C meeting and discussion with the FDA is warranted. The purpose of this meeting is to review the XRx ...

EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's ...

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA ...